After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...

Teva Pharmaceuticals (TEVA) secures exclusive global rights to a biosimilar candidate targeting Roche’s (RHHBY) multiple ...

Roche’s biggest bet in the Alzheimer’s disease space may be its phase 3-stage amyloid asset, but the Swiss pharma is keeping its options open when it comes to targeting tau. Tau is one of two proteins ...

New biotech Avere Therapeutics has taken a fast-track to becoming a publicly listed company by merging with NextCure, with a ...

An anonymous NFC executive had two words to describe New York Jets linebacker Demario Davis ahead of the 2026 season. The post Anonymous NFL Exec Has 2 Words for Jets LB Demario Davis appeared first ...

Alector faces a strategic reset after GSK’s termination of their neuroscience collaboration, shifting the investment case to ...

Insilico Medicine and China Medical System Holdings announced on July 12, 2026, a second AI-driven drug discovery collaboration in fewer than three months, with the specific brain-disease target ...

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals ...

Pennsylvania residents will soon be able to access behavioral healthcare even if they’re out of state or move away, thanks to a bill that passed 188-14 in the state House ...